SK pharmteco’s Joyce Fitzharris Named Chairperson of BioPharmaChem Ireland
Dublin, Ireland – [October 21, 2024] – SK pharmteco, a global contract development and manufacturing organization (CDMO) for small molecules
SK pharmteco offers integrated CDMO services across Cell and Gene Therapy, Small Molecule, and Analytical Services for drug substances and products
Built on 80 years of experience, SK pharmteco is a trusted partner specializing in the manufacture of APIs and intermediates, cell and gene therapy technologies, registered starting materials and analytical services for the pharmaceutical industry worldwide. Our global operations have the capability and capacity to support your needs from development through commercial production.
Our complementary assets and expertise enable us to provide the highest quality services to our customers.
SK pharmteco is a global contract development and manufacturing organization (CDMO) with sixmanufacturing facilities across the U.S., Europe, and Korea. The company partners with biopharmaceutical companies to manufacture active pharmaceutical ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and perform analytical services. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.
SK pharmteco is a leader in operational excellence and continuous improvement. Our highly skilled team delivers innovative solutions utilizing advanced technologies:
We provide PAI and full regulatory support as well as complete confidentiality. We have a strong record of environmental, health, and safety performance. All our plants have been successfully audited by global regulatory agencies, including the FDA (US), EMA (Europe), PMDA (Japan), and MFDS (Korea).
With a strong technology toolbox and ~815 m³ (~215,450 gal) of global small molecule capacity and two facilities dedicated to large molecules, we have the capability and capacity to support your needs across the full lifecycle.
The most trusted global partner in the delivery of innovative medicine
We are committed to changing the world through our unwavering dedication to life-saving therapies.
We enable our partners with cutting-edge technology, expertise and customer centricity, allowing them to bring breakthrough treatments to patients and delivering happiness and health to stakeholders everywhere.
Diazomethane, Azide, Hydrazine, Ozone
Fixed bed, CSTR, PAT
Process Development, CGT Analysis, Viral Vector Development & CGMP Manufacturing, Plasmid DNA Manufacturing, & Cell Therapy Manufacturing
Simulated Moving Bed (SMB), Batch
Up to 4 m3 (~1,000 gal) scale
Down to 10 ng/m3 containment
Crystallization, Micronization
Dublin, Ireland – [October 21, 2024] – SK pharmteco, a global contract development and manufacturing organization (CDMO) for small molecules
Date: November 12-14 Location: Hamburg, Germany Venue: Hamburg Congress Center Come meet with the following team members: Pedro Couto Rosado Rachel
FOR IMMEDIATE RELEASE PARIS, France and HEIDELBERG, Germany (October 2, 2024) – SK pharmteco, a global contract development and manufacturing
"*" indicates required fields